Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer

YUDAI HOJO; TOSHIHIKO TOMITA; MASATAKA IGETA; MOTOKI MURAKAMI; SHUGO KOHNO; EIICHIRO NAKAO; YOSHITAKA KITAYAMA; TATSURO NAKAMURA; YASUNORI KURAHASHI; YOSHINORI ISHIDA; SEIICHI HIROTA; SHINICHIRO SHINZAKI; HISASHI SHINOHARA

doi:10.21873/anticanres.17583

Research ArticleClinical Studies

Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer

YUDAI HOJO, TOSHIHIKO TOMITA, MASATAKA IGETA, MOTOKI MURAKAMI, SHUGO KOHNO, EIICHIRO NAKAO, YOSHITAKA KITAYAMA, TATSURO NAKAMURA, YASUNORI KURAHASHI, YOSHINORI ISHIDA, SEIICHI HIROTA, SHINICHIRO SHINZAKI and HISASHI SHINOHARA

Anticancer Research May 2025, 45 (5) 2091-2102; DOI: https://doi.org/10.21873/anticanres.17583

YUDAI HOJO

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIHIKO TOMITA

2Department of Gastroenterology, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MASATAKA IGETA

3Department of Biostatistics, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MOTOKI MURAKAMI

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SHUGO KOHNO

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

EIICHIRO NAKAO

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOSHITAKA KITAYAMA

2Department of Gastroenterology, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TATSURO NAKAMURA

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YASUNORI KURAHASHI

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOSHINORI ISHIDA

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SEIICHI HIROTA

4Department of Surgical Pathology, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SHINICHIRO SHINZAKI

2Department of Gastroenterology, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HISASHI SHINOHARA

1Department of Gastroenterological Surgery, Faculty of Medicine, Hyogo Medical University, Nishinomiya, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: shinohara{at}hyo-med.ac.jp

Article
Figures & Data
Info & Metrics
PDF

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

PreviousNext

In this issue

Anticancer Research

Vol. 45, Issue 5

May 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 19 + 1 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer

Anticancer Research May 2025, 45 (5) 2091-2102; DOI: 10.21873/anticanres.17583

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer

Anticancer Research May 2025, 45 (5) 2091-2102; DOI: 10.21873/anticanres.17583

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

No citing articles found.

Google Scholar

Keywords

Gastric cancer
Nivolumab
Chemotherapy
conversion surgery
conversion therapy

Main menu

User menu

Search

Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer

Purchase access

patientACCESS

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords